We aimed to study the effect of atorvastatin, a statin, on cholesterol synthesis and absorption and VLDL-apoB metabolism in obese men with the metabolic syndrome. METHODS: A total of 25 dyslipidaemic obese men were randomized to atorvastatin (n ¼ 13) (40 mg/day) or matching placebo (n ¼ 12) for 6 weeks. Hepatic secretion and fractional catabolic rate (FCR) of VLDL-apoB was measured using an intravenous bolus of d 3 -leucine before and after treatment. ApoB isotopic enrichment was measured using GCMS and multicompartmental modelling. Plasma lathosterol: cholesterol and campesterol:cholesterol ratios were determined to assess cholesterol synthesis and cholesterol absorption, respectively. RESULTS: Compared with placebo, atorvastatin significantly decreased (Po0.05) total cholesterol, triglyceride, LDL-cholesterol and VLDL-apoB. Plasma lathosterol:cholesterol ratio decreased from 26.472.4 to 8.870.8, while the campesterol:cholesterol ratio increased from 26.574.4 to 38.675.8 (Po0.01). Atorvastatin also increased VLDL-apoB FCR from 3.8270.33 to 6.3070.75 pools/day (Po0.01), but did not significantly alter VLDL-apoB secretion (12.871.7 to 13.872.0 mg/kg/day). CONCLUSIONS: In obesity, atorvastatin inhibits cholesterogenesis but increases intestinal cholesterol absorption. The increased cholesterol absorption may counteract the inhibitory effect on hepatic VLDL-apoB secretion, but it does not apparently influence enhanced catabolism of VLDL-apoB.
Introduction
The metabolic syndrome is characterized by central obesity and defective apolipoprotein B-100 (apoB) metabolism that may increase the risk of cardiovascular disease. 1 Hepatic oversecretion of apoB is a key abnormality in central obesity 2 because of adipose tissue and hepatic insulin resistance and increased lipid substrate availability to the liver. 3, 4 Metabolic syndrome patients also have abnormal cholesterol homeostasis, reflected by increased body cholesterol synthesis and decreased cholesterol absorption efficiency. 2, 5 Cholesterol absorption efficiency is reflected by the plasma concentrations of plant sterols, particularly campesterol. 6 The therapeutic consequences of inhibiting cholesterol synthesis on both hepatic secretion of apoB and cholesterol absorption
have not yet been investigated in the metabolic syndrome. We hypothesized that statin therapy would increase cholesterol absorption and that this might affect hepatic apoB secretion. 7 
Materials and methods
We carried out a randomized, double-blind, placebo-controlled trial of the effect of 6 weeks of atorvastatin treatment, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the kinetics of VLDL-apoB metabolism and cholesterol absorption in 25 insulin-resistant men with central obesity (waist circumference 4102 cm) and dyslipidaemia (plasma triglycerides 41.7 mmol/l or HDL-cholester-ol o1.0 mmol/l). 8 None had diabetes mellitus, apoE2/E2 genotype, macroproteinuria, creatinaemia (4120 mmol/l), hypothyroidism, abnormal liver enzymes, or consumed 430 g alcohol/day. None reported a history of cardiovascular disease or was taking agents affecting lipid metabolism. The study was approved by the local Ethics Committee. Blood samples were taken at baseline and 6 weeks after randomization. Fasting plasma for triglycerides, LDL-cholesterol and HDL-cholesterol were assayed using standard enzymatic methods. ApoA-I and B-100 were determined by immunonephelometry. Plasma insulin was measured by radioimmunoassay. Plasma glucose was estimated by a hexokinase method, and insulin resistance by a homeostasis model assessment (HOMA) score. 2 ApoE genotype was determined as described previously. 2 Liver and muscle enzymes were analysed using routine methods. Dietary intake was assessed serially using 24 h dietary diaries (Xyris Software, Queensland, Australia). VLDL kinetics were measured using an intravenous bolus injection of d 3 -leucine, as described in detail elsewhere. 2 ApoB isotopic enrichment was measured using GCMS, and production and fractional catabolic rate (FCR) of VLDL apoB was derived using multicompartmental modelling (SAAM-II). Plasma lathosterol and campesterol concentrations were measured by gas-liquid chromatography [5] [6] [7] and expressed in mmol Â 10 2 per mol of cholesterol. Data were analysed by analysis of covariance using general linear models.
Results
The subjects were middle-aged (mean7s.d., 5279 y), normotensive (blood pressure 130716/79711 mm Hg), centrally obese (waist circumference 114711 cm, body weight 104713 kg, BMI 3374 kg/m 2 ) and insulin resistant (HOMA score 7.973.1). A total of 18 subjects were E3/E3 homozygotes, one was E2/E3 heterozygote, five were E3/E4 heterozygotes and one was E4/E4. The average daily energy and nutrient intake (mean7s.d.) was: 10 03171390 kJ, 3276% energy from fat, 4279% energy from carbohydrates, 1974% energy from protein and 775% energy from alcohol; none of these variables differed between groups at baseline or changed significantly within groups during the study. There were no untoward clinical or biochemical side effects of treatment.
Compared with the placebo group (n ¼ 12), atorvastatin (n ¼ 13) resulted in significant decreases (Po0.001) in plasma cholesterol (À37%, from 5.870.2 to 3.670.1 mmol/l), triglycerides (À26%, from 1.970.1 to 1.470.1 mmol/l), non-HDL-cholesterol (À48%, from 4.870.2 to 2.570.1 mmol/l), LDL-cholesterol (À52%, from 3.870.2 to 1.870.1 mmol/l) and apo B-100 (À44%, 12376 to 6871 mg/ dl); HDL-cholesterol and apo A-I increased by 75% (from 1.0070.05 to 1.0570.05 mmol/l) and 73% (from 11975 to 12374 mg/dl), respectively, but these differences were not significant. Atorvastatin significantly decreased the plasma pool size of VLDL-apoB (À27%, Po0.001), and increased the FCR of VLDL-apoB (þ 58%, Po0.001) (Figure 1) . However, the secretion rate of VLDL-apoB did not alter significantly during treatment. With atorvastatin, the plasma lathosterol:cholesterol ratio decreased by 67% and the campesterol:cholesterol ratio increased by 46% (both Po0.01) (Figure 2 ).
Discussion
Compelling evidence shows that the availability of hepatic cholesterol determines apoB secretion by the liver. 3 We Effect of a statin on hepatic apolipoprotein B-100 GF Watts et al previously showed that statins decrease apoB secretion in normolipidaemic and familial hypercholesterolaemia subjects. 9, 10 That hepatic apoB secretion did not fall in the present study was unexpected, probably because of a compensatory increase in a specific cholesterol pool in the liver resulting from either increased gastrointestinal absorption, or reduction in biliary cholesterol excretion, following statin therapy.
In support of the former possibility is the demonstration that addition of dietary plant stanols in diabetics on pravastatin lowers plasma plant sterols, decreases cholesterol absorption and results in incremental reduction in LDL-apoB production. 7 On the other hand, a recent study showed an inverse correlation between biliary cholesterol secretion and plasma plant sterol levels, 11 and simvastatin was previously demonstrated to decrease biliary cholesterol secretion. 12 Therefore, it is likely that the increase in the plasma campesterol:cholesterol ratio we observed reflects an analogous effect of atorvastatin on biliary cholesterol secretion rather than increased cholesterol absorption. Direct measurement of the latter has failed to show consistent effects of other statins. 7, 13, 14 However, a decrease in biliary cholesterol secretion could also lead to an increase in cholesterol absorption, as shown in mice 15 and in dietary studies in humans. 16 Low cholesterol absorption efficiency in obesity may be because of an increased biliary cholesterol pool that competes with dietary cholesterol and noncholesterol sterols for intestinal absorption. 5 Weight reduction decreases cholesterol synthesis 4 and biliary cholesterol excretion, and elevates cholesterol absorption in obesity, 5 consistent with a reversal of these mechanisms. Our study suggests that statins may have a similar effect on cholesterol homeostasis in obesity. Atorvastatin nevertheless decreased the pool size of VLDL-apoB and lowered plasma triglycerides by increasing VLDL-apoB catabolism. Elevated plasma apoB results from hepatic oversecretion of apoB and, with insulin resistance, is a powerful risk factor for cardiovascular events. 17 Increased hepatic production of apoB may also independently predict coronary risk. 18 We suggest that optimal regulation of the kinetics of apoB in the metabolic syndrome following statin therapy will require inhibition of cholesterol absorption with either a drug such as ezetimibe 19 or with dietary plant sterols. 7 A similar therapeutic approach may also apply to effects of weight reduction, 5 but these hypotheses require further evaluation.
The significance of these investigations also relies on the notion that a large proportion of the interindividual variation in cholesterol absorption is genetically determined. 20 In subjects with the metabolic syndrome, atorvastatin inhibits cholesterogenesis, but increases plasma campesterol levels, suggestive of decreased biliary cholesterol secretion and/or increased cholesterol absorption. These changes may counteract the inhibitory effect of statins on hepatic VLDLapoB secretion, but do not apparently influence the effect of statins in enhancing the catabolism of VLDL-apoB. Effect of a statin on hepatic apolipoprotein B-100 GF Watts et al
